Effectiveness of Zonisamide in the Treatment of Alcohol Dependent Veterans

唑尼沙胺治疗酒精依赖退伍军人的有效性

• 批准号: 8819717
• 负责人: ALBERT JOSEPH ARIAS
• 金额: --
• 依托单位: VA CONNECTICUT HEALTHCARE SYSTEM
• 依托单位国家: 美国
• 财政年份: 2015
• 资助国家: 美国
• 起止时间: 2015-10-01 至 2020-09-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8819717
• 关键词: Adherence; Adverse effects; Afghanistan; Aftercare; Alcohol consumption; Alcohol dependence; Alcoholism; Anticonvulsants; Anxiety Disorders; Behavior Therapy; Biological Markers; Clinical; Consumption; Depressive disorder; Development; Diagnosis; Disease remission; Disulfiram; Dopamine; Dose; Double-Blind Method; Effectiveness; Functional disorder; Funding; General Population; Generic Drugs; Genes; Genetic Polymorphism; Genotype; Glutamates; Goals; Grant; Heavy Drinking; High Prevalence; Individual; Injection of therapeutic agent; Iraq; Measures; Medical; Medicine; Mental disorders; Methodology; Methods; Military Personnel; Mood Disorders; Naltrexone; Neurotransmitters; Outcome; Outcome Assessment; Outcome Measure; Patient-Focused Outcomes; Pharmaceutical Preparations; Pharmacogenetics; Pharmacologic Actions; Pharmacology; Pilot Projects; Placebo Control; Placebos; Population; Prevalence; Public Health; Randomized; Regimen; Resources; Sampling; Serotonin; Services; System; TimeLine; United States; United States Food and Drug Administration; Veterans; Vietnam; Work; acamprosate; alcohol craving; alcohol use disorder; alcoholism therapy; cost; craving; dosage; double-blind placebo controlled trial; drinking; effectiveness clinical trial; experience; follow-up; impression; improved outcome; innovation; men; personalized medicine; primary care setting; primary outcome; public health relevance; topiramate; translational neuroscience; treatment response; trial design

DESCRIPTION (provided by applicant): Title: Effectiveness of Zonisamide in the Treatment of Alcohol-Dependent Veterans ABSTRACT: Veterans have a high prevalence of alcohol dependence (AD), and those with AD also have a high rate of co-occurring psychiatric illnesses. Zonisamide is an extremely promising medicine for treating AD and managing other clinical problems including psychiatric disorders. Zonisamide is an affordable, generic anticonvulsant with unique actions on the major neurotransmitter systems involved in alcoholism, and it has neuroprotective effects. We recently completed a randomized, placebo- controlled pilot study of zonisamide in treating AD that showed significant reductions in heavy drinking, overall drinking, and alcohol craving. Zonisamide was very well tolerated in this study. In this application, we propose a larger (N = 160), 14-week, randomized, double-blind, placebo-controlled, effectiveness study of zonisamide in reducing heavy drinking and improving outcomes in a representative population of heavy-drinking veterans with AD. We describe zonisamide's potential to break through the barriers in the treatment of veterans with AD as well as its unique pharmacology that brings innovation to alcoholism treatment. An inexpensive, hypothesis-driven, exploratory, translational, pharmacogenetic component adds to the innovation and will work towards optimizing outcomes and personalizing treatment for veterans.

描述（由申请人提供）： 标题：Zonisamide在依赖酒精依赖的退伍军人摘要中的有效性：退伍军人的酒精依赖性（AD）较高，并且患有AD的人的同时发生精神病患者也很高。 Zonisamide是一种非常有前途的药物，用于治疗AD和管理其他临床问题，包括精神疾病。 Zonisamide是一种负担得起的通用抗惊厥药，对涉及酒精中毒的主要神经递质系统具有独特的作用，并且具有神经保护作用。最近，我们完成了一项随机，安慰剂控制的试点研究，用于治疗AD，该研究显示出大量饮酒，整体饮酒和渴望酒精的降低。在这项研究中，锌酶胺的耐受性很好。在此应用中，我们提出了更大的（n = 160），14周，随机，双盲，安慰剂对照，Zonisamide的有效性研究，以减少大量饮酒和改善AD的代表性退伍军人的代表性人群的结果。我们描述了Zonisamide在用AD治疗退伍军人方面打破障碍的潜力以及其独特的药理学，从而将创新带入酒精中毒治疗。廉价，假设驱动的，探索性的，转化的，药物遗传学成分增加了创新，并将致力于优化对退伍军人的结果和个性化治疗。